(Bloomberg) -- Theranos Inc., the heralded Silicon Valley blood-testing startup facing scrutiny over the accuracy of its technology, said it has scaled back the use of proprietary finger-pricking technique to a single test out of the 200 it offers.
The decision limits the use of a technology that has helped Theranos raise venture-capital funding at a valuation of about $10 billion and has drawn interest from high-profile partners.
Now Theranos is using the same blood-testing equipment as competitors it’s attempting to challenge, such as Quest Diagnostics Inc. and Laboratory Corp. of America Holdings.
Recommended For You
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
